Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12384633 | 0.92 | EPHX2 (0.44) | EPHX2CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL24477829 | 0.88 | SMYD3 (0.38) | EPHX2CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL25456270 | 0.88 | EPHX2 (0.33) | EPHX2CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL20111649 | 0.87 | CYP2D6 (0.33) | EPHX2CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL20111712 | 0.83 | ACLY (0.34) | CYP2D6KCNH2HRH3ACLYDDIT3 | |
| SCHEMBL22959646 | 0.83 | CYP2D6 (0.37) | EPHX2CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL1104697 | 0.80 | TP53 (0.46) | CYP2D6KCNH2HRH3ACLYALDH1A1 | |
| SCHEMBL26470411 | 0.80 | CA1 (0.42) | EPHX2CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL21732885 | 0.80 | CYP2D6 (0.47) | CYP2D6KCNH2HRH3ACLY | |
| SCHEMBL21732723 | 0.80 | ACLY (0.33) | CYP2D6KCNH2HRH3ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | OSCOTEC INC. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | OSCOTEC INC. (KR) | 2021-11-25 | — | — | US | disclosed |
| WO-2019112269-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | 주식회사 오스코텍 | 2019-06-13 | — | — | WO | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363144-A1 | PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR | LRRK2, PARK7, WEE1 | EPHX2 4493/4885CYP2D6 4268/4885KCNH2 3970/4885 |
| US-11370796-B2 | Substituted pyrazoles as LRRK2 inhibitors | LRRK2, PARK7, PAK3 | EPHX2 4190/4885CYP2D6 3415/4885KCNH2 2358/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | EPHX2 669/4885CYP2D6 274/4885KCNH2 2385/4885 |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CCR10, CXCR3 | EPHX2 1853/4885CYP2D6 1032/4885KCNH2 672/4885 |
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | CDK2, CDK6, CDK20 | EPHX2 2810/4885CYP2D6 429/4885KCNH2 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.